Stock 688393 GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Guangzhou LBP Medicine Science & Technology Co., Ltd.

Equities

688393

CNE1000043R4

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
18 CNY +4.23% Intraday chart for Guangzhou LBP Medicine Science & Technology Co., Ltd. +10.70% -27.91%
Apr. 23 LBP Medicine Scraps Convertible Bonds Issuance Plans MT
Apr. 19 LBP Medicine Gets Certificate for HER2 Antibody Reagent MT

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 3,452 2,844 2,053 2,336
Enterprise Value (EV) 1 2,606 2,219 1,812 2,245
P/E ratio 33.9 x 35.8 x 48.9 x 59.5 x
Yield 0.76% 0.89% 0.64% -
Capitalization / Revenue 9.19 x 6.48 x 4.05 x 4.7 x
EV / Revenue 6.94 x 5.06 x 3.57 x 4.51 x
EV / EBITDA 29.6 x 29.6 x 33.5 x 38.5 x
EV / FCF 454 x -18.1 x -26.4 x -21.1 x
FCF Yield 0.22% -5.52% -3.79% -4.74%
Price to Book 2.96 x 2.36 x 1.67 x 1.85 x
Nbr of stocks (in thousands) 93,340 93,340 93,340 93,568
Reference price 2 36.98 30.47 22.00 24.97
Announcement Date 4/13/21 4/1/22 4/20/23 4/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 306.3 355.2 375.4 439 507.4 497.3
EBITDA 1 83.26 94.73 88 75.04 54.14 58.37
EBIT 1 70.87 83.4 77.89 58.8 22.74 20.17
Operating Margin 23.14% 23.48% 20.75% 13.39% 4.48% 4.06%
Earnings before Tax (EBT) 1 74.47 87.25 99.85 88.72 28.79 16.85
Net income 1 61.47 73.99 84.75 79.78 42.69 40.06
Net margin 20.07% 20.83% 22.57% 18.17% 8.41% 8.06%
EPS 2 0.8800 1.060 1.090 0.8500 0.4500 0.4200
Free Cash Flow 1 10.45 33.78 5.743 -122.6 -68.66 -106.4
FCF margin 3.41% 9.51% 1.53% -27.92% -13.53% -21.39%
FCF Conversion (EBITDA) 12.55% 35.66% 6.53% - - -
FCF Conversion (Net income) 17% 45.66% 6.78% - - -
Dividend per Share - - 0.2800 0.2700 0.1400 -
Announcement Date 8/14/20 8/14/20 4/13/21 4/1/22 4/20/23 4/22/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 132 171 846 625 242 91.9
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 10.5 33.8 5.74 -123 -68.7 -106
ROE (net income / shareholders' equity) 17% 17.5% 10.4% 6.33% 2.41% 1.71%
ROA (Net income/ Total Assets) 9.97% 10.3% 5.32% 2.77% 1.03% 0.9%
Assets 1 616.7 720 1,593 2,885 4,143 4,437
Book Value Per Share 2 5.540 6.330 12.50 12.90 13.20 13.50
Cash Flow per Share 2 1.070 1.220 6.810 2.330 0.9700 0.7200
Capex 1 43.9 35.5 62.4 143 72.2 37.7
Capex / Sales 14.34% 10.01% 16.63% 32.65% 14.22% 7.59%
Announcement Date 8/14/20 8/14/20 4/13/21 4/1/22 4/20/23 4/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY CO., LTD. Stock Guangzhou LBP Medicine Science & Technology Co., Ltd.
-27.91% 232M
BIOMÉRIEUX Stock bioMérieux
+1.19% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+3.60% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-14.33% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
-5.02% 1.64B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 688393 Stock
  4. Financials Guangzhou LBP Medicine Science & Technology Co., Ltd.